Le Lézard
Classified in: Health
Subject: ATY

Dentsply Sirona Investor Alert: Hagens Berman Alerts Dentsply Sirona, Inc. Investors to Investigation of Potential Securities Law Violations Connected to SEC Enforcement Inquiry and Management Shakeup

SAN FRANCISCO, Oct. 6, 2017 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors that it is investigating Dentsply Sirona, Inc. (NASDAQ: XRAY) for possible securities law violations.  If you purchased or otherwise acquired securities of Dentsply Sirona before October 3, 2017 and suffered losses contact Hagens Berman Sobol Shapiro LLP.  For more information visit:


or contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing


Hagens Berman Sobol Shapiro LLP

On August 9, 2017, Dentsply Sirona announced in its Form 10-Q filing that the SEC's Division of Enforcement "has asked the Company to provide documents and information concerning the Company's accounting and disclosures, including its accounting and disclosures relating to transactions with a significant distributor of the Company."  In reaction, Dentsply Sirona's share price fell $5.18, or 8.4%, to close at $56.23 on August 9, 2017.

On October 2, 2017, Dentsply Sirona announced that three top executives tendered their resignations: CEO Jeffrey Slovin, Executive Chairman Bret Wise, and President and Chief Operating Officer Christopher Clark.  This news drove the price of Dentsply Sirona shares down $3.48, or 5.8%, to close at $56.33 on October 2, 2017.

The next day, The Wall Street Journal reported the Company's board forced these executives out.

"We're focused on the matters triggering the SEC's inquiry, the extent of improper accounting if any, and the possible roles of the recently-departed executives," said Hagens Berman partner Reed Kathrein.

Whistleblowers: Persons with non-public information regarding Dentsply Sirona should consider their options to help in the investigation or take advantage of the SEC Whistleblower Program.  Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email XRAY@hbsslaw.com.

About Hagens Berman 
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 11 offices across the country.  The firm represents investors, whistleblowers, workers and consumers in complex litigation.   More about the firm and its successes can be found at www.hbsslaw.com.  For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Reed Kathrein, 510-725-3000

SOURCE Hagens Berman Sobol Shapiro LLP

These press releases may also interest you

at 17:56
Prometic Life Sciences Inc. ("Prometic") today provided an update regarding its clinical development programs and confirmation of its priorities regarding its lead drug...

at 17:27
Delta 9 Cannabis Inc.  ("Delta 9" or the "Company") today announced that it has granted, effective today, an aggregate of 376,500 stock options (each an "Option") to certain directors, officers, employees and consultants of the Company in accordance...

at 17:16
Diplomat Pharmacy, Inc. announced today that it will release its fourth quarter and 2017 year end financial results and provide 2018 guidance on Monday, February 26, 2018 after market close, with a conference call to follow at 5:00 p.m. ET....

at 16:50
Asm. Autumn Burke (D-Inglewood) today introduced legislation that aims to boost the learning potential of California's students by sending them to school with healthy eyes and clear vision on the first day of class. AB 2444 is sponsored by the State...

at 16:43
Johnson & Johnson will participate in the Cowen 38th Annual Healthcare Conference on Tuesday, Mar. 13, at The Boston Marriott Copley Place, Boston. Ashley McEvoy, Company Group Chairman, Consumer Medical Devices will represent the Company in a...

at 16:43
The Chairman of Cedrus Investments ("Cedrus"),Mr. Rani Jarkas, is invited as the keynote speaker at the Asian Investment Series of the Hong Kong Biotech Invest & Partnering 2018 conference to be held on 13th March 2018 in Hong Kong. Cedrus has been...

News published on 6 october 2017 at 09:30 and distributed by: